eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 LOS ANGELES, CA / ACCESS Newswire/ March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these resu ...

Core Insights - eXoZymes Inc. has achieved a significant validation milestone for its cell-free biomanufacturing platform through a successful pilot scale run conducted by Cayman Chemical, demonstrating the technology's scalability and reliability [1][3] Group 1: Technology Validation - Cayman Chemical utilized eXoZymes' technology transfer package to scale up from a one-liter setup to a 100-liter pilot run, successfully managing real-world conditions that typically challenge enzyme-based processes [2] - The pilot run produced over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) with a purity of 99.6%, showcasing a high level of efficiency with a 99% conversion rate of feedstock to end product [2][3] Group 2: Industry Impact - The successful pilot run is expected to facilitate partnerships for formulation development, product validation, and application-specific testing, allowing companies to move beyond feasibility studies [3][4] - eXoZymes aims to lead the market in biomanufacturing by offering advanced enzymes, termed "exozymes," which can replace traditional petrochemical processes and enhance sustainability [7][8]

Core Insights - eXoZymes is set to present a solution for scaling production of NCT, a naturally occurring small molecule with potential applications in nutraceuticals and pharmaceuticals, at the MISTA Symposium on March 18, 2026 [1] - The focus of the presentation will be on NCT's role in metabolic health and its relevance in the evolving landscape of food, supplements, and wellness solutions [1] - The company aims to leverage its proprietary exozyme platform to enable efficient production of NCT, addressing the historical limitations of its rarity in nature [1] Company Overview - eXoZymes Inc. was founded in 2019 and has developed a biomanufacturing platform that utilizes AI-enhanced enzymes, termed "exozymes," to produce valuable natural products sustainably [1] - Exozymes operate outside living cells, allowing for scalable production and replacing traditional toxic petrochemical processes [1] - The company does not intend to trademark the term "exozymes," viewing it as a new nomenclature for the next generation of biomanufacturing [1] Industry Context - The MISTA Symposium will gather leaders from the food, nutrition, and health industries to discuss scientific advances that support healthier aging and improved metabolic resilience [1] - NCT has gained attention for its potential metabolic benefits, which could open new opportunities in the nutraceutical, pharmaceutical, and specialty ingredient markets [1] - The advancements in cell-free enzyme engineering are expected to facilitate the scalable production of previously impractical molecules [1]

Core Insights - The latest issue of Manufacturing Digital highlights global leaders and breakthrough technologies shaping the future of sustainability, technology, biopharmaceuticals, and supply chain [1] Group 1: Fujifilm's Innovations - Fujifilm aims to become the TSMC of the biopharmaceutical industry, focusing on trust as a foundational element [3] - The company employs a zero-defect manufacturing philosophy and expertise in materials chemistry to achieve breakthroughs in semiconductors and biopharmaceuticals [4] - Fujifilm is pioneering EUV lithography materials for next-generation chips and developing modular biomanufacturing networks for vaccines and cell therapies [4] Group 2: Supply Chain Evolution - Mourad Tamoud, Chief Supply Chain Officer at Schneider Electric, discusses the transformation of supply chains from operational necessities to strategic differentiators [5][6] - Modern supply chains are positioned to drive growth, sustainability, and resilience while integrating digital technologies and aligning with broader business strategies [7] - The focus is on fostering an environment of innovation and continuous improvement within supply chain operations [6] Group 3: Sustainability and Supply Chain Portfolio - BizClik's Sustainability and Supply Chain portfolio includes five magazines that provide authoritative insights and influence decision-makers across these sectors [8][9] - The portfolio aims to shape industry conversations and serve as a trusted source of information [9] Group 4: Upcoming Events - BizClik is organizing its annual global summits focused on sustainability and supply chain, starting with Sustainability LIVE: The Net Zero Summit [10] - The event will gather over 2,000 attendees to discuss the intersection of sustainability and supply chains, aiming to accelerate collective impact [11]

Group 1 - The core viewpoint of the articles emphasizes the integration of technological innovation and industrial innovation as a driving force for economic development, particularly in the context of China's strategic industries [1][5][14] - The completion of Beijing Rocket Street marks a significant milestone in commercial aerospace, facilitating a comprehensive ecosystem for rapid demand matching within the industry [1] - The production line for T1000-grade carbon fiber in Shanxi is a breakthrough in high-end materials, crucial for aerospace and defense, overcoming previous technological barriers [3][5] Group 2 - The application of AI in traditional industries, such as dairy production, showcases the deep integration of digital technologies, enhancing efficiency and traceability across the supply chain [7] - The artificial intelligence industry in China is experiencing rapid growth, with a projected scale exceeding 1.2 trillion yuan, reflecting a 30% increase from the previous year [7] - The low-altitude economy is transitioning from pilot projects to large-scale implementation, with significant policy support and the establishment of multiple eVTOL pilot cities [8] Group 3 - The role of enterprises in driving technological innovation is increasingly recognized, with state-owned enterprises significantly increasing R&D investments, reaching 890.16 billion yuan in 2025 [12] - Mechanisms to facilitate the transformation of scientific achievements into practical applications are being strengthened, with universities granting greater ownership of research outcomes to incentivize innovation [12][13] - The collaborative efforts among various stakeholders, including universities and government bodies, are fostering a comprehensive ecosystem for technology transfer and commercialization [14]

Core Insights - Multiply Labs has achieved a significant milestone in scaling the production of cell and gene therapies by utilizing NVIDIA's open Isaac and GR00T technologies, which include advanced robotics simulation and perception [1] Company Developments - The company is recognized as a leader in robotic biomanufacturing, indicating its strong position in the industry [1] - The adoption of advanced technologies marks a pivotal shift from traditional manual processes to more automated and efficient methods in the production of cell and gene therapies [1] Industry Impact - The integration of robotics in biomanufacturing is expected to transform the cell and gene therapy landscape, which has historically depended on artisanal production methods [1] - Cell and gene therapies are highlighted as life-changing treatments, emphasizing their potential impact on healthcare [1]

Our mission here at Motiv Labs is to develop robotic systems that enable the manufacturing of advanced next generation therapies at scale and [music] affordably. The roads we developed which you can see behind me are effectively robotic factories for next generation therapies. Inside the system uh there are actually several robotic arms and the robotic arms move the therapies from one module to the next.[music] So these are rows are designed to make as many therapies as possible as cheaply as possible becau ...

Core Insights - Liberation Bioindustries has successfully closed the first tranche of its Series A1 equity round [1] - The company is nearing completion of its first commercial-scale precision fermentation biomanufacturing facility [1] - The facility will have a production capacity of 600,000 liters and a fully dedicated downstream process [1]

Core Insights - eXoZymes Inc. has successfully achieved a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process [1] - The scale-up utilizes a proprietary exozyme-based, cell-free biomanufacturing platform with a conversion level exceeding 99% from feedstock to product [1] Company Developments - The achievement represents a significant milestone in the scalability of the eXoZymes platform [1] - eXoZymes is recognized as a pioneer in AI-enhanced enzymes that convert sustainable feedstock into nutraceuticals and new medicines [1]

Summary of Dyadic International Conference Call - December 09, 2025 Company Overview - **Company**: Dyadic International (NasdaqCM:DYAI) - **Industry**: Biomanufacturing, Life Sciences, Food Nutrition, Bio-Industrial Markets - **Focus**: Scalable, animal-free recombinant protein solutions Key Points and Arguments 1. **Commercial Inflection Point**: Dyadic is at a significant commercial inflection point with multiple products entering the market and active revenue engines [2][4][30] 2. **Transition from R&D to Commercialization**: The company has shifted focus from R&D and grant-based revenues to commercial applications, particularly in non-therapeutic areas that do not require FDA review [3][5][30] 3. **Product Launch Timeline**: Dyadic expects multiple product launches starting in 2025 and continuing through 2027, with a focus on life sciences, food nutrition, and bio-industrial segments [4][10][32] 4. **Platform Technologies**: The company utilizes two main platforms, C1 and Dapibus, designed for speed, productivity, scale, and low cost, to produce recombinant animal-free protein solutions [7][9][30] 5. **Market Segments**: - **Life Sciences**: Focus on cell culture media, cell and gene therapy, and high-value proteins like human transferrin and albumin [11][15][19] - **Food Nutrition**: Targeting the alternative protein market, particularly non-animal dairy and functional food proteins, with a market size estimated at $50-$70 billion [12][22] - **Bio-Industrial**: Re-entering the market through partnerships, focusing on cellulosic enzymes with a market size of approximately $6 billion [13][14][23] 6. **Revenue Generation Strategy**: Dyadic employs a three-pillar strategy: buy, brand, and build, allowing for direct sales, licensing, and partnerships to monetize its technology [9][10][19] 7. **Partnerships**: Collaborations with companies like Proliant Health and Fermbox Bio are expected to drive revenue growth and product launches [16][23][29] 8. **Regulatory Advantages**: The focus on non-therapeutic products allows for faster market entry, with timelines of 12-18 months from proof of concept to revenue [5][18][31] 9. **Financial Projections**: The company anticipates meaningful revenue growth starting in early 2026, with a revenue run rate of approximately $12 million needed to reach cash flow positive status [33][37] Additional Important Information - **Innovation and Technology**: Dyadic has access to CRISPR technology, enhancing its ability to optimize production strains [4][30] - **Market Trends**: The shift towards sustainable and predictable proteins is driving demand for Dyadic's products, particularly in the context of growing consumer preference for non-animal sources [3][12] - **Future Outlook**: The company is positioned for significant growth with a layered revenue approach, leveraging existing partnerships and expanding its product portfolio [26][27][32] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.